Skip to main content

Table 1 Body Composition Variables

From: Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males

 

300 mg

600 mg

Week

0

1

3

8

11

0

1

3

8

11

ECF (L)

19.6 ± 2.5

19.9 ± 3.1

19.6 ± 2.4

19.5 ± 2.3

20.0 ± 2.5

19.8 ± 3.1

20.2 ± 3.3

20.0 ± 2.7

20.2 ± 3.3

21.2 ± 3.1

ICF (L)

30.0 ± 5.1

30.3 ± 5.3

30.0 ± 5.0

29.2 ± 4.2

29.9 ± 4.8

29.5 ± 6.2

29.7 ± 5.0

29.9 ± 4.5

30.6 ± 6.4

32.5 ± 5.8

TBW (L)

49.5 ± 7.4

50.2 ± 8.1

49.6 ± 7.2

48.7 ± 6.2

49.9 ± 7.0

49.3 ± 9.2

49.8 ± 8.2

49.9 ± 7.2

50.8 ± 9.6

53.6 ± 8.7

Fat Mass (kg)

12.2 ± 6.3

12.4 ± 6.2

12.5 ± 6.2

13.0 ± 5.5

13.0 ± 5.8

12.1 ± 3.5

12.5 ± 3.3

12.4 ± 3.5

12.1 ± 3.2

12.6 ± 3.4

Fat-Free Mass (kg)

64.5 ± 7.7

64.6 ± 8.0

64.1 ± 7.5

63.9 ± 8.7

64.0 ± 8.1

69.0 ± 12.1

68.9 ± 12.4

68.8 ± 11.1

69.9 ± 12.0

70.1 ± 13.2

Total Body Mass (kg)

79.3 ± 13.2

79.6 ± 13.7

79.3 ± 12.9

79.5 ± 13.0

78.8 ± 13.8

81.1 ± 13.3

81.5 ± 13.8

81.3 ± 12.8

82.0 ± 13.5

82.7 ± 14.7

Body Fat (%)

14.7 ± 5.4

14.9 ± 5.2

15.1 ± 5.3

15.9 ± 4.7

15.8 ± 4.9

15.0 ± 4.2

15.4 ± 4.0

15.3 ± 3.9

14.8 ± 3.6

15.3 ± 3.8

  1. No significant differences in body composition were observed during the 11 weeks (p > 0.05).